Pancreatic Cancer Trial Roundup

This month’s trials include several important themes: new KRAS-targeted drugs for KRAS G12D and other KRAS mutations, engineered T-cell therapies for very specific KRAS and HLA combinations, antibody-drug conjugates, an MTAP-deletion strategy, precision imaging for PSCA-expressing pancreatic cancer, and local treatment approaches for unresectable tumors or symptomatic metastases.

Some trials are specifically for pancreatic ductal adenocarcinoma, while others enroll several solid tumors but include pancreatic cancer patients in the right clinical situation. Several require tumor testing, such as KRAS G12D, KRAS G12V, HLA-A11:01, MTAP deletion, PSCA expression, or basal-type pancreatic cancer markers.

If one of these looks close to your situation, let us know if we can help connect you. Even when a trial is not a perfect match, it can still help you understand where treatment options may be headed.

Subscribe now

🔍 SEARCH TIP: Find Listings Matched to Your Situation

✅ 16 NEW PANCREATIC CANCER TRIALS

• 3 Trials for Newly Diagnosed Advanced or Metastatic Pancreatic Cancer

• 9 Trials for Advanced or Metastatic Pancreatic Cancer After Prior Treatment

• 3 Trials for Localized, Borderline Resectable, Locally Advanced, or Unresectable Pancreatic Cancer

• 1 Trial for Symptom Relief or Local Control of Metastases

Trials for Newly Diagnosed Advanced or Metastatic Pancreatic Cancer

A KRAS G12D pill added to first treatment for metastatic pancreatic cancer

This phase 3 trial tests zoldonrasib, also called RMC-9805, an oral drug designed to block KRAS G12D. KRAS is one of the most common drivers of pancreatic cancer, and KRAS G12D is a frequent pancreatic cancer mutation. Participants receive usual first treatment chemotherapy — either modified FOLFIRINOX or gemcitabine plus Abraxane — plus either zoldonrasib or placebo.

The usual first treatment for metastatic pancreatic cancer often relies on chemotherapy. For many patients, there has not been a KRAS-directed targeted therapy option. This trial asks whether adding a KRAS G12D-targeted pill to chemotherapy can improve outcomes compared with chemotherapy alone.

Expect to be assigned to receive zoldonrasib or placebo with chemotherapy. You will not be told which you are receiving. Participants should expect tumor testing for KRAS G12D, regular scans, labs, side-effect monitoring, and chemotherapy visits.

This could be relevant for patients whose metastatic pancreatic cancer has a KRAS G12D mutation and who are starting first treatment.

🏥 Available in Atlanta, GA | NCT07621718

An AXL inhibitor added to FOLFIRINOX and immunotherapy for first treatment

This phase 1/1b trial tests AB801, an oral drug that blocks AXL, a receptor involved in cancer invasion, immune resistance, and treatment resistance. For pancreatic cancer, AB801 is combined with zimberelimab, a PD-1 immunotherapy drug, plus FOLFIRINOX chemotherapy.

Immunotherapy has not helped most pancreatic cancer patients unless the tumor has specific biomarkers such as MSI-H / dMMR. This trial asks whether blocking AXL can make chemotherapy and immunotherapy work better together in newly treated pancreatic cancer.

Expect oral medication, IV chemotherapy, IV immunotherapy, scans, labs, and close safety monitoring. This is an early-phase study, so safety and dose-finding are major goals.

This could be relevant for patients starting treatment for borderline resectable, locally advanced, or metastatic pancreatic cancer who are fit enough for an intensive combination.

🏥 Available in Los Angeles, CA | NCT07619313

A KRAS G12D pill alone or with Erbitux for metastatic pancreatic cancer

This phase 2 study tests VS-7375, an oral KRAS G12D inhibitor. One part studies VS-7375 alone in patients who are newly diagnosed or have received little prior treatment for metastatic pancreatic cancer. Another part combines VS-7375 with cetuximab, also known as Erbitux, an EGFR-targeting antibody, in previously treated metastatic pancreatic cancer.

KRAS G12D is a major pancreatic cancer driver, but direct KRAS G12D targeting is still a developing area. Adding EGFR blockade is a rational strategy because cancer cells can sometimes use EGFR signaling as a workaround when the KRAS pathway is blocked.

Expect tumor testing for KRAS G12D, oral targeted therapy, possible IV cetuximab depending on the study group, scans, labs, and close monitoring for side effects.

This could be relevant for patients with KRAS G12D metastatic pancreatic cancer, including some starting treatment and some whose cancer has already been treated.

🏥 Available in West Valley City, UT | NCT07644559

Need help?

Want help finding trials that match your exact diagnosis, treatments, and biomarkers? Sagely Health offers a free personalized trial report. Share a few details — or upload records you already have — and get a short, clear report focused on the trial options worth discussing.

---

✅ Free · ✅ Confidential · ✅ Oncologist-reviewed

---

Get my free trial report

Trials for Advanced or Metastatic Pancreatic Cancer After Prior Treatment

A KRAS G12V cell therapy designed to recognize pancreatic cancer cells

This phase 1 study tests TCR1188-ABC, a personalized cell therapy made from a patient’s own T cells. The T cells are engineered to recognize KRAS G12V when it is presented by HLA-A11:01. The cells are also designed to interact with ILT4-positive immune-suppressing cells in the tumor environment.

KRAS G12V is a driver mutation in a subset of pancreatic cancers. TCR-T therapy is a highly personalized immune treatment, but solid tumors can be hard for immune cells to attack. This study tries to address both tumor recognition and the immune-suppressive tumor environment.

Expect tumor and HLA testing, collection and manufacturing of T cells, chemotherapy to prepare the body for the cell infusion, a single engineered T-cell infusion, and close monitoring for immune side effects such as cytokine release syndrome.

This could be relevant for a small subset of patients with metastatic KRAS G12V pancreatic cancer who also have the required HLA type.

🏥 Available in Philadelphia, PA | NCT07594067

A pan-KRAS pill for KRAS-mutant pancreatic cancer after prior treatment

This phase 1/2 trial tests BLU-924, also called SAR449336, an oral pan-KRAS inhibitor. Unlike drugs aimed at one specific KRAS mutation, this drug is designed to target multiple KRAS-mutant cancers. The study includes pancreatic cancer, non-small cell lung cancer, and colorectal cancer.

Most pancreatic cancers have a KRAS mutation, but not all have the same KRAS subtype. A broader KRAS inhibitor could matter if it works across multiple KRAS variants. This is a first-in-human study, so safety, dosing, and early signs of activity come first.

Expect oral treatment, tumor testing for KRAS mutation, dose-escalation monitoring, scans, labs, and possible treatment in combination cohorts depending on the study part.

This could be relevant for patients with metastatic KRAS-mutant pancreatic cancer whose cancer has progressed after prior treatment.

🏥 Available in Fairfax, VA | NCT07629960

A RAS G12D TCR-T cell therapy for advanced solid tumors

This phase 1 trial tests MSK-TCR5, an engineered T-cell therapy designed to recognize RAS G12D mutations, including KRAS G12D, when presented by HLA-A11:01. The therapy uses a patient’s own T cells, which are modified and then given back.

KRAS G12D is common in pancreatic cancer, but this treatment also requires a specific HLA type. This makes it relevant to a smaller subset of patients. The study is early, and the main goals are safety, dose-finding, and learning whether the engineered T cells can persist and show activity.

Expect tumor testing for RAS G12D, HLA testing, T-cell collection, cell manufacturing, infusion of engineered cells, scans, labs, and intensive monitoring.

This could be relevant for patients with KRAS G12D pancreatic cancer who have already received prior therapy and meet the HLA requirement.

🏥 Available at multiple NY/NJ sites, including Montvale, Commack, Harrison, Uniondale, Basking Ridge, and Middletown | NCT07638371

A PRMT5 inhibitor plus pemetrexed for MTAP-deleted tumors

This phase 1b/2 basket study tests navlimetostat, also called BMS-986504, with pemetrexed chemotherapy. Navlimetostat is designed to exploit a weakness in tumors with MTAP deletion by targeting PRMT5-related biology. Pemetrexed is an antifolate chemotherapy that interferes with building blocks cancer cells need to grow.

MTAP deletion creates a specific vulnerability in some cancers. This study asks whether combining a PRMT5 inhibitor with pemetrexed can be useful for MTAP-deleted tumors, including a GI cancer group that includes pancreatic cancer.

Expect tumor testing for MTAP deletion, oral navlimetostat, IV pemetrexed every 21-day cycle, scans, blood tests, and safety monitoring.

This could be relevant for patients with metastatic pancreatic cancer whose tumor has MTAP deletion.

🏥 Available in Chicago, IL | NCT07594626

A new antibody-drug conjugate with a TOP1 chemotherapy payload

This phase 1 study tests IM-1617, an antibody-drug conjugate, or ADC. ADCs are designed to attach to a target on cancer cells and deliver a linked chemotherapy payload more directly into the tumor. IM-1617 carries a topoisomerase I inhibitor payload, a type of chemotherapy payload also used in some other modern ADCs.

Several ADCs have become important in other cancers, but pancreatic cancer still has limited ADC options. This study is early and uses a target that has not been publicly disclosed, so safety, dosing, and early signs of activity are the focus.

Expect IV treatment, dose-escalation monitoring, scans, labs, and close tracking of side effects. Tumor testing may be required depending on the study part.

This could be relevant for patients with advanced pancreatic cancer who have already received available usual treatments and are looking at early-phase trial options.

🏥 Available in Irving, TX | NCT07578571

A two-target ADC aimed at EGFR and MUC1

This phase 1 study tests NEOK002, also called ABL209, a bispecific antibody-drug conjugate. “Bispecific” means it is designed to bind two targets — EGFR and MUC1 — before delivering an exatecan-class topoisomerase I inhibitor payload into cancer cells.

EGFR and MUC1 are cancer-associated targets, but tumors can be heterogeneous, meaning not all cells look the same. A two-target ADC is designed to improve tumor selectivity and payload delivery. This is a first-in-human study, so safety and dosing come first.

Expect IV ADC treatment, possible tumor testing, scans, labs, and close safety monitoring. Patients with recent exposure to a topoisomerase I payload ADC may not qualify.

This could be relevant for patients with advanced pancreatic cancer who have exhausted usual options and are considering early ADC trials.

🏥 Available in Dallas, Houston, Austin, and San Antonio, TX; New York, NY; Nashville, TN; and Fairfax, VA | NCT07612189

A two-target ADC aimed at B7-H3 and ROR1

This phase 1 study tests NEOK001, also called ABL206, a bispecific antibody-drug conjugate. It is designed to bind B7-H3 and ROR1, two tumor-associated surface targets, and deliver a linked chemotherapy payload into cancer cells.

B7-H3 and ROR1 are being studied across several cancers. A dual-target ADC may help address tumor heterogeneity, though this is still an early-stage idea. The first goal is to find a safe dose and watch for early signs of tumor response.

Expect IV treatment, dose-escalation monitoring, scans, labs, and side-effect tracking.

This could be relevant for patients with advanced pancreatic cancer after prior treatment if their disease fits the solid-tumor eligibility requirements.

🏥 Available in Nashville, TN; Austin, San Antonio, Dallas, and Houston, TX; Fairfax, VA; and New York, NY | NCT07612176

An immune-stimulating nanoparticle treatment for advanced solid tumors

This phase 1/2 study tests UI-102, an IV immune-stimulating drug packaged in a nanoparticle. It activates TLR7/8, immune sensors that can stimulate certain immune cells, including macrophages and dendritic cells. The nanoparticle design is intended to help direct the immune stimulation toward myeloid cells.

Pancreatic cancer often has an immune-suppressive tumor environment. This study asks whether changing the immune environment around tumors could become a useful treatment strategy. It is an early study, so safety, dosing, and immune effects are major goals.

Expect IV infusions, dose-escalation monitoring, blood tests, scans, and research testing to understand immune effects.

This could be relevant for patients with advanced pancreatic cancer after prior treatment who are considering early immunotherapy-based studies.

🏥 Available in Houston, Dallas, and San Antonio, TX | NCT07605962

A new tubulin drug combined with Keytruda

This phase 1/2 trial tests PM54, a tubulin inhibitor, in combination with pembrolizumab, also known as Keytruda. Tubulin inhibitors interfere with the internal structure cancer cells need to divide. Keytruda blocks PD-1, a brake on immune cells.

Keytruda alone usually helps pancreatic cancer patients only when the tumor has certain biomarkers, such as MSI-H / dMMR. This study asks whether a new chemotherapy-like drug can pair with PD-1 blockade in advanced solid tumors after prior treatment. It is not specific to pancreatic cancer, but pancreatic cancer patients may fit if they meet the solid-tumor criteria.

Expect IV treatment, dose-finding in the early part, scans, labs, and monitoring for immune-related side effects and chemotherapy-type side effects.

This could be relevant for patients with advanced pancreatic cancer after prior treatment who are considering broad solid-tumor studies.

🏥 Available in Fort Worth, Houston, and Irving, TX; Fairfax, VA; and New York, NY | NCT07644039

Trials for Localized, Borderline Resectable, Locally Advanced, or Unresectable Pancreatic Cancer

A short pre-treatment study for basal-type pancreatic cancer

This phase 1b study tests samuraciclib, an oral CDK7 inhibitor, before planned chemotherapy and/or surgery. CDK7 helps control gene transcription and the cell cycle. This trial gives the drug for a short window before other treatment so researchers can study whether it changes tumor biology.

Basal-type pancreatic cancer is a subgroup that may behave more aggressively and may respond differently to some treatments. This trial is not mainly designed to replace surgery or chemotherapy. It is designed to learn whether CDK7 inhibition affects this specific pancreatic cancer biology.

Expect tumor testing for GATA6 and HMGA2, a 14-day course of oral treatment, research biopsy through endoscopic ultrasound, CT imaging, blood draws, and then planned usual treatment such as chemotherapy and/or surgery.

This could be relevant for patients with localized or locally advanced pancreatic cancer whose tumor has basal-type features.

🏥 Available in Seattle, WA | NCT07645651

A pulsed electric field procedure for unresectable pancreatic tumors

This early feasibility study tests the Aliya pulsed electric field system. The procedure is done through endoscopic ultrasound, using a needle-based approach to deliver high-voltage electrical pulses into the tumor. The goal is to damage cancer cell membranes without relying on heat.

Local procedures in the pancreas are challenging because the tumor can sit near important blood vessels, ducts, and organs. This study asks whether a non-thermal ablation approach can be delivered safely in unresectable pancreatic tumors. It is a local treatment study, not a whole-body treatment.

Expect endoscopic ultrasound, fine-needle aspiration for diagnosis, the ablation procedure, anesthesia or sedation planning, imaging, labs, and close monitoring after the procedure.

This could be relevant for patients with unresectable pancreatic tumors where a local procedure is being considered as part of a broader treatment plan.

🏥 Available in Columbus, OH | NCT07619417

A PSCA-targeted PET scan to map pancreatic cancer

This phase 1 imaging study tests a PET tracer called 64Cu-DOTA-A2DM. It is designed to attach to PSCA, a protein found on a substantial subset of pancreatic cancers, and deliver a small radioactive signal that can be seen on PET imaging.

Pancreatic cancer can be difficult to biopsy and track. A PSCA-targeted scan could help researchers see where PSCA is present in the body and may support future PSCA-directed treatments. This study is about imaging and safety, not directly treating the cancer.

Expect IV infusion of the imaging agent, PET scans over 1–2 days, blood and urine sampling, and safety monitoring.

This could be relevant for patients with unresectable locally advanced or metastatic pancreatic cancer whose tumor expresses PSCA.

🏥 Available in Duarte, CA | NCT07608627

Trial for Symptom Relief or Local Control of Metastases

A specialized radiation approach for metastatic tumors needing local control

This randomized phase 2 trial tests LATTICE radiation, a specialized form of stereotactic radiation. Instead of giving the same dose evenly across the whole tumor, LATTICE radiation gives a lower background dose to the full tumor and very high-dose “peaks” to small areas inside the tumor. It is compared with a more conventional 5-treatment palliative radiation schedule.

Palliative radiation is often used to reduce pain, bleeding, pressure, or other symptoms from metastatic tumors. This study asks whether a different radiation geometry can improve local control or symptom relief while still protecting nearby normal tissue.

Expect a computer to assign participants to one of two radiation approaches, radiation planning scans, five radiation treatments, symptom tracking, and follow-up imaging.

This could be relevant for pancreatic cancer patients with a metastatic tumor site where local radiation is being considered for symptoms or control.

🏥 Available in Palo Alto, CA | NCT07594431

Do you need help finding trials that may fit your situation or getting connected?

Sagely Health offers a free, oncologist-reviewed Personalized Clinical Trial Shortlist for people with pancreatic cancer and other cancers. Share a few details—or upload records you already have—and receive a short, clear report focused on trials that may fit your diagnosis, treatments, biomarkers, and location.

Get Started

✍🏻 Do you have feedback? We’re listening at info@sagelyhealth.com or leave a comment!

Subscribe now

Pancreatic Cancer Trial Roundup

Each month, we scan newly opened pancreatic cancer trials and translate the trial language into plain English: who it may apply to, what the treatment is trying to do, and why it might be worth knowing about.

This update includes several trials for pancreatic ductal adenocarcinoma, especially for tumors with KRAS mutations, KRAS G12D, KRAS wild-type disease, MTAP deletion, EphA2, CLDN18.2, SWI/SNF alterations, or severe cancer-related weight loss.

🔍 SEARCH TIP: Find Listings Matched to Your Situation

✅ 23 NEW PANCREATIC CANCER TRIALS

• 1 Trial After Surgery / To Reduce Recurrence Risk

• 4 Trials for Borderline Resectable, Locally Advanced, or Unresectable Pancreatic Cancer

• 9 Trials for First Treatment of Metastatic or Advanced Pancreatic Cancer

• 9 Trials for Recurrent or Metastatic Pancreatic Cancer After Prior Treatment

1 Trial After Surgery / To Reduce Recurrence Risk

KRAS-targeting pill after surgery for high-risk pancreatic cancer

This study tests daraxonrasib, also called RMC-6236, after pancreatic cancer has been removed with surgery. Daraxonrasib is a pill designed to block active RAS signaling. That matters because KRAS mutations are found in about 90% of pancreatic cancers, making KRAS one of the most important targets in this disease.

After surgery, many people receive chemotherapy such as modified FOLFIRINOX or gemcitabine-based treatment to lower the risk of the cancer coming back. Even with surgery and chemotherapy, the recurrence risk can still be high. This trial asks whether adding a KRAS-targeting drug after those treatments can help keep the cancer away longer.

Expect an oral study drug with regular clinic visits, labs, and scans to watch for recurrence. This is an adjuvant study, meaning the goal is to reduce the chance the cancer returns after earlier treatment.

A rare pancreatic cancer trial focused on preventing recurrence after surgery, using a drug aimed at one of the disease’s most common drivers.

🏥 Available globally, with sites across U.S. | NCT07252232

4 Trials for Borderline Resectable, Locally Advanced, or Unresectable Pancreatic Cancer

Focused ultrasound to help FOLFIRINOX reach pancreatic tumors

This trial tests IMD10, a focused ultrasound cavitation device, together with FOLFIRINOX. FOLFIRINOX is a common pancreatic cancer chemotherapy combination that includes 5-FU, leucovorin, irinotecan, and oxaliplatin. The goal of the device is to use ultrasound energy to help chemotherapy reach the tumor more effectively.

Pancreatic tumors can be difficult for drugs to penetrate because they often have dense scar-like tissue around them. This trial asks whether using ultrasound during chemotherapy can improve drug delivery and help more tumors shrink, become removable, or stay controlled.

Expect standard FOLFIRINOX chemotherapy plus scheduled ultrasound-based treatments, with scans to measure response. The study compares treatment with the device against chemotherapy alone.

A practical device-plus-chemo trial for people hoping to improve tumor shrinkage before surgery or control locally advanced disease.

🏥 Available in San Antonio, TX; Boston, MA; Charlottesville, VA; and South Korea | NCT07325214

EGFR antibody treatment for rare KRAS wild-type pancreatic cancer

This trial tests panitumumab, an EGFR-targeting antibody also known by the brand name Vectibix, with chemotherapy in pancreatic cancer that does not have a KRAS mutation. This is important because most pancreatic cancers do have KRAS mutations; KRAS wild-type pancreatic cancer is uncommon, likely in the single-digit percentage range.

EGFR antibodies such as Vectibix and cetuximab (Erbitux) are better known in colorectal cancer, where they can help some patients whose tumors are RAS wild-type. This trial asks whether the same idea could help the rare group of pancreatic cancer patients whose tumors do not have KRAS-driven resistance to EGFR targeting.

Expect IV chemotherapy plus IV panitumumab, with tumor testing to confirm KRAS wild-type status. Visits, labs, side-effect checks, and scans are part of the study schedule.

For the small group of patients with KRAS wild-type pancreatic cancer, this offers a biomarker-matched approach using a familiar EGFR-targeting drug.

🏥 Available at many U.S. sites | NCT06998940

NanoKnife electric-pulse ablation for unresectable pancreatic cancer

This study tests NanoKnife irreversible electroporation, often called IRE. NanoKnife uses short electrical pulses delivered through needles to damage cancer cells. Unlike heat-based ablation, IRE is designed to treat tumors near sensitive structures such as blood vessels, which is one reason it has been explored in pancreatic cancer.

For unresectable pancreatic cancer, usual care often includes chemotherapy such as FOLFIRINOX or gemcitabine/Abraxane, sometimes followed by radiation. This trial asks whether adding NanoKnife can safely treat the local pancreatic tumor and help with outcomes such as pain, quality of life, or local control.

Expect an interventional procedure using the NanoKnife system, plus follow-up visits, imaging, pain assessments, and quality-of-life questionnaires. This is a procedure-based study, not a pill or IV drug trial.

A local treatment option for people whose pancreatic tumor cannot be removed with surgery but remains a major focus of the disease.

🏥 Available in Englewood, NJ | NCT06937996

Maintenance immune therapy after pancreatic cancer stabilizes on chemotherapy

This trial tests Imprime PGG plus mitazalimab after pancreatic cancer has already responded to or stayed stable on first treatment. Imprime PGG is an immune-activating drug designed to stimulate parts of the innate immune system. Mitazalimab is an antibody that targets CD40, a signal involved in immune activation.

The idea is to use immune stimulation after chemotherapy has already gained some control. This is different from trying to replace chemotherapy up front. Standard first treatments for advanced pancreatic cancer often include FOLFIRINOX, NALIRIFOX, or gemcitabine/Abraxane; this trial looks at what can be done after that first control point.

Expect IV immune-based treatment after initial chemotherapy response or stability, with regular labs, side-effect checks, and scans. Eligibility depends on how the cancer responded to earlier chemotherapy.

A maintenance-style trial for people whose pancreatic cancer has not grown on first treatment and who want a strategy aimed at extending that control.

🏥 Available in Philadelphia, PA | NCT07199764

Need help?

Want help finding trials that match your exact diagnosis, treatments, and biomarkers? Sagely Health offers a free personalized trial report. Share a few details — or upload records you already have — and get a short, clear report focused on the trial options worth discussing.

✅ Free · ✅ Confidential · ✅ Oncologist-reviewed

---

Get my free trial report

9 Trials for First Treatment of Metastatic or Advanced Pancreatic Cancer

Pan-RAS pill plus chemotherapy, or alone, for first treatment of metastatic pancreatic cancer

This Phase 3 trial tests daraxonrasib, also called RMC-6236, in first treatment for metastatic pancreatic cancer. Daraxonrasib is a pill designed to block active RAS signaling. This is a major target in pancreatic cancer because about 90% of pancreatic cancers have KRAS mutations.

Participants may receive daraxonrasib alone, daraxonrasib plus gemcitabine/Abraxane, or gemcitabine/Abraxane alone. Gemcitabine and Abraxane are a common first treatment for metastatic pancreatic cancer. This study asks whether adding or using a RAS-targeting drug can help people live longer or keep the cancer controlled longer than chemotherapy alone.

Expect to be randomly assigned to one of the treatment groups. Treatment may include an oral study pill, IV chemotherapy, or both, with regular labs, scans, and side-effect monitoring. There is no placebo-only group.

One of the most important pancreatic cancer trials because it tests a broad KRAS/RAS-targeting drug directly against a standard first chemotherapy option.

🏥 Available in Henderson, NV and Maumee, OH | NCT07491445

MEK-targeting pill added to gemcitabine/Abraxane for first treatment of metastatic pancreatic cancer

This Phase 3 trial tests atebimetinib, a pill that blocks MEK1/2, with a modified schedule of gemcitabine/Abraxane. MEK is part of a growth-signal system that is often active downstream of KRAS. Because KRAS mutations are so common in pancreatic cancer, researchers have long tried to block related signals such as MEK.

Gemcitabine/Abraxane is a familiar first treatment for metastatic pancreatic cancer. This study asks whether adding atebimetinib and adjusting the chemotherapy schedule can help people live longer than standard gemcitabine/Abraxane alone.

Expect IV gemcitabine/Abraxane, with or without an oral MEK-targeting study drug, depending on random assignment. Visits include labs, side-effect checks, and scans. There is no placebo-only group.

A broad pancreatic cancer trial that tries to improve a familiar chemotherapy backbone without requiring a rare biomarker.

🏥 Available in Maumee, OH; Nashville, TN; and New York, NY | NCT07562152

KRAS G12D pill plus first chemotherapy for metastatic pancreatic cancer

This Phase 3 trial tests INCB161734, a pill designed to block KRAS G12D, with first-line chemotherapy. KRAS G12D is one of the most common KRAS mutations in pancreatic cancer, found in roughly 35% to 40% of pancreatic cancers. That makes it one of the biggest possible targets in this disease.

Participants receive INCB161734 or placebo with a standard chemotherapy option chosen by the study team, such as modified FOLFIRINOX or gemcitabine/Abraxane. This trial asks whether directly targeting KRAS G12D can improve outcomes when added to the chemotherapy many patients would otherwise receive.

Expect tumor genomic testing to confirm KRAS G12D. Participants are randomly assigned to study drug or placebo, both given with active chemotherapy. Visits include labs, scans, and side-effect checks.

For people with KRAS G12D pancreatic cancer, this is one of the most important trials trying to make KRAS status guide first treatment.

🏥 Available globally, with many U.S. sites plus Canada, Europe, Japan, Australia, and South Korea | NCT07522073

KRAS G12D degrader added to FOLFIRINOX-style first treatment

This trial tests setidegrasib, a KRAS G12D degrader, with intensive first chemotherapy such as modified FOLFIRINOX or NALIRIFOX. A degrader is different from a blocker: instead of only trying to shut off the KRAS G12D protein, it aims to help the cell break it down.

KRAS G12D is common in pancreatic cancer, affecting roughly 35% to 40% of patients. FOLFIRINOX-style treatment is often used for people who are fit enough for intensive chemotherapy. This study asks whether adding a KRAS G12D degrader can improve tumor shrinkage or delay growth beyond chemotherapy alone.

Expect tumor testing to confirm KRAS G12D, then chemotherapy with the study drug according to the trial schedule. Visits include labs, scans, and close side-effect monitoring because FOLFIRINOX-style treatment can be demanding.

A frontline trial for KRAS G12D pancreatic cancer that tries to go beyond blocking KRAS by removing the problem protein.

🏥 Available at sites across U.S. and Japan | NCT07409272

Stress-hormone receptor blocker added to gemcitabine/Abraxane

This trial tests relacorilant with gemcitabine/Abraxane as first treatment for metastatic pancreatic cancer. Relacorilant blocks the glucocorticoid receptor, a stress-hormone receptor that may help some cancers survive chemotherapy pressure.

Gemcitabine/Abraxane is one of the most common first treatments for metastatic pancreatic cancer. This trial asks whether blocking glucocorticoid receptor signaling can make that chemotherapy work better or help people stay controlled longer.

Expect IV gemcitabine/Abraxane plus the study drug on a repeating schedule, with regular labs, side-effect checks, and scans. The trial is testing whether the add-on improves outcomes compared with the chemotherapy backbone.

A first-treatment option for metastatic pancreatic cancer that tries to make a familiar chemotherapy regimen more effective.

🏥 Available in San Antonio, TX | NCT07259317

TEAD-targeting pill added to gemcitabine/Abraxane for pancreatic cancer

This study tests ODM-212, a pill that blocks TEAD proteins, with gemcitabine/Abraxane in a pancreatic cancer cohort. TEAD is involved in cancer growth and survival signals, including signals linked to the Hippo/YAP system. This is not a standard pancreatic cancer target yet, but it is an active area of drug development.

The pancreatic cancer part of the trial combines ODM-212 with gemcitabine/Abraxane, a standard treatment backbone. The goal is to see whether adding TEAD blockade can safely improve tumor shrinkage or disease control.

Expect IV gemcitabine/Abraxane plus an oral study drug, with regular labs, scans, and safety checks. This is part of a broader multi-cancer trial, but the pancreatic cancer arm is specific.

A new targeted add-on to gemcitabine/Abraxane for people with advanced pancreatic cancer, especially those interested in trials beyond KRAS.

🏥 Available in Fairfax, VA and Irving, TX | NCT07563738

PRMT5-targeting drug plus chemotherapy for MTAP-deleted pancreatic cancer

This trial tests BMS-986504, also known as MRTX1719, with chemotherapy in pancreatic cancer that has MTAP deletion. MTAP deletion is a smaller biomarker group, often estimated around 10% to 15% across many cancers, and likely a minority of pancreatic cancers. It is usually found through tumor genomic testing.

MTAP-deleted tumors may have a weakness involving an enzyme called PRMT5. BMS-986504 is designed to take advantage of that weakness. This study asks whether adding a PRMT5-targeting drug to chemotherapy can help control pancreatic cancer in this biomarker-defined group.

Expect tumor testing to confirm MTAP deletion, then chemotherapy with the study drug. Visits include labs, scans, and side-effect monitoring. This is a biomarker-matched trial, so the MTAP result is central.

For patients with MTAP-deleted pancreatic cancer, this is a more personalized trial built around a specific tumor weakness.

🏥 Available in Houston, TX | NCT07283705

CCR8 plus PD-1 immunotherapy added to gemcitabine/Abraxane

This trial tests BMS-986340 plus nivolumab (Opdivo) with gemcitabine/Abraxane. BMS-986340 targets CCR8, a marker linked to certain immune-suppressing cells in tumors. Nivolumab is a PD-1 immunotherapy drug. The goal is to reduce immune suppression and make the tumor more vulnerable while chemotherapy is being used.

Standard immunotherapy by itself usually does not work well for most pancreatic cancers, except for rare MSI-H / dMMR tumors. This study uses immunotherapy differently: it combines immune modulation with a standard chemotherapy backbone in first treatment.

Expect IV chemotherapy plus IV immunotherapy drugs, with regular clinic visits, labs, scans, and immune-related side-effect monitoring. This is an active-treatment combination trial.

A first-treatment trial trying to make immunotherapy more useful in pancreatic cancer by pairing it with chemotherapy and a second immune target.

🏥 Available in Scottsdale, AZ; Jacksonville, FL; and Rochester, MN | NCT07226856

Anti-GDF15 treatment for weight loss during first treatment for metastatic pancreatic cancer

This trial tests ponsegromab, an antibody that blocks GDF15, together with first-line chemotherapy for metastatic pancreatic cancer. GDF15 is a protein linked to appetite loss, weight loss, and cancer cachexia. Cachexia is more than ordinary weight loss: it can involve loss of muscle, weakness, poor appetite, and difficulty staying strong during treatment.

Unlike most pancreatic cancer trials, this study is focused heavily on weight loss, appetite, strength, and function—not just whether tumors shrink. It asks whether blocking GDF15 can help people better maintain their body weight and strength while receiving chemotherapy such as FOLFIRINOX or gemcitabine/Abraxane. That matters because weight loss and weakness can make it harder to tolerate treatment and maintain quality of life.

Expect first-line chemotherapy plus the study drug, with regular weight, appetite, strength, lab, and safety checks. Scans still monitor the cancer, but symptom and weight-related outcomes are central.

A patient-centered trial for one of pancreatic cancer’s most difficult problems: staying strong enough to continue treatment.

🏥 Available in Illinois, Nevada, and Puerto Rico, plus Australia, Israel, and Japan; 12 locations total | NCT06989437

9 Trials for Recurrent or Metastatic Pancreatic Cancer After Prior Treatment

EphA2-targeted toxin delivery after first treatment for metastatic pancreatic cancer

This trial tests BT5528 in metastatic pancreatic cancer that expresses EphA2. EphA2 is a target found on some cancer cells and tumor blood vessels. The drug is a Bicycle toxin conjugate, meaning it uses a small targeting structure to deliver a toxic payload to EphA2-positive cancer cells.

Many people in this setting have already received first treatment such as FOLFIRINOX, NALIRIFOX, or gemcitabine/Abraxane. Later options may include Onivyde with 5-FU/leucovorin or other chemotherapy. This trial asks whether EphA2 can guide delivery of a targeted toxin after first-line treatment stops working.

Expect testing to confirm EphA2 expression, followed by IV study treatment, labs, side-effect checks, and scans. This is a post–first-line trial and does not use a placebo-only group.

A targeted-delivery option for people whose pancreatic cancer expresses EphA2 and has grown after first treatment.

🏥 Available in Philadelphia, PA | NCT07450859

Pitavastatin added after pancreatic cancer stays stable on gemcitabine-based treatment

This trial tests whether pitavastatin can be added to gemcitabine/Abraxane after the cancer has stayed controlled on gemcitabine-based treatment. Pitavastatin is a cholesterol-lowering statin. In cancer research, statins are being studied because they may affect cell-growth signals and tumor metabolism.

This is not for someone whose cancer is rapidly growing on gemcitabine/Abraxane. It is for people who have had at least initial disease control and are continuing treatment. The study asks whether adding pitavastatin can help extend that control.

Expect daily oral pitavastatin or no pitavastatin along with ongoing gemcitabine/Abraxane, depending on the study assignment. Visits include labs, scans, and side-effect checks.

A low-cost drug-repurposing trial for people whose pancreatic cancer has already shown some control on gemcitabine-based treatment.

🏥 Available in Orange, CA | NCT07549958

Immunotherapy plus gemcitabine for SWI/SNF-altered metastatic pancreatic cancer

This trial tests cemiplimab (Libtayo), a PD-1 immunotherapy drug, with gemcitabine in metastatic pancreatic cancer with SWI/SNF alterations. SWI/SNF is a group of genes involved in how DNA is packaged and read inside cells. Alterations in these genes occur in a smaller subset of cancers and may change how tumors respond to treatment.

Most pancreatic cancers do not respond well to standard immunotherapy alone. This trial focuses on a biomarker-selected group where the tumor biology may be different. Gemcitabine is a familiar pancreatic cancer chemotherapy drug, and cemiplimab is being added to see whether immune therapy can help in this specific subset.

Expect tumor genomic testing to confirm a SWI/SNF alteration, followed by IV gemcitabine and IV cemiplimab. Visits include labs, immune side-effect monitoring, and scans.

A niche but important trial for people whose pancreatic tumor testing shows a SWI/SNF alteration.

🏥 Available in La Jolla, CA | NCT06790602

Personalized multi-antigen T-cell therapy for unresectable or metastatic pancreatic cancer

This trial tests MT-601, an adoptive T-cell therapy made from a patient’s own immune cells. The treatment is designed to recognize multiple tumor-associated antigens instead of just one target. That may matter in pancreatic cancer because tumors can be mixed and may escape if only one target is attacked.

Patients first have immune cells collected through apheresis. The cells are then prepared and later infused back during a planned treatment window. The study focuses on safety, dose, and early signs of cancer control.

Expect a cell-collection procedure, time for the cell product to be made, then infusion of MT-601 with close monitoring. Eligibility depends on prior treatment and whether the cancer is not actively progressing on certain chemotherapy regimens.

A personalized immune-cell therapy for people with advanced pancreatic cancer whose disease is controlled enough to allow time for cell manufacturing.

🏥 Available in Houston, TX | NCT07554521

Belzutifan plus TROP2-targeted CAR-NK cells for advanced pancreatic cancer

This trial tests belzutifan plus engineered CAR-NK cells that target TROP2. Belzutifan is a HIF-2α inhibitor, a drug that affects how cancer cells respond to low-oxygen stress. The CAR-NK cells are immune cells engineered to recognize TROP2, a marker found in several cancers, including some pancreatic cancers.

The NK cells are also designed with IL-15 support and TGFBR2 knockout, which are meant to help them survive and resist immune-suppressing signals around the tumor. This is a complex early trial, but it is clearly aimed at advanced pancreatic cancer where standard choices are limited.

Expect screening, cellular therapy logistics, close monitoring after treatment, labs, scans, and possible intraperitoneal and IV delivery depending on the study plan. This is an early safety-focused study.

A high-intensity immune-cell therapy trial for advanced pancreatic cancer, built to attack both tumor stress biology and immune suppression.

🏥 Available in Houston, TX | NCT07377526

KRAS G12D pill for advanced pancreatic cancer after standard treatment

This study tests D3S-003, a pill designed to block KRAS G12D. Although the study also enrolls other cancers with KRAS G12D, pancreatic cancer is one of the most important matches because KRAS G12D is found in roughly 35% to 40% of pancreatic cancers.

This is a first-in-human study, so the main goal is finding a safe dose. Researchers will also watch closely for tumor shrinkage or whether the cancer stays stable. For people who have already received treatments such as FOLFIRINOX, NALIRIFOX, gemcitabine/Abraxane, or Onivyde/5-FU, this trial offers a more direct attempt to target one of pancreatic cancer’s most common mutations.

Expect a daily oral pill, frequent visits early in treatment, blood tests, and scans. The study starts with dose finding and does not use a placebo-only group.

A strong biomarker-matched option for pancreatic cancer patients whose tumor testing shows KRAS G12D.

🏥 Available in San Antonio, TX | NCT07456046

Pan-KRAS pill for KRAS-mutated pancreatic cancer after standard treatment

This study tests KST-6051, a pill designed to block multiple KRAS mutation types. That is highly relevant in pancreatic cancer because about 90% of pancreatic cancers have a KRAS mutation, but not all have the same KRAS subtype.

Most KRAS drugs in development focus on one mutation, such as KRAS G12D or KRAS G12C. KST-6051 is broader. That could make it relevant for pancreatic cancer patients whose tumor has KRAS G12V, G12R, G12D, or another KRAS mutation, depending on the study rules. For many patients in this situation, standard options may include FOLFIRINOX, NALIRIFOX, gemcitabine/Abraxane, and later Onivyde/5-FU-based therapy.

Expect an oral study drug, regular labs, clinic visits, and scans. This is an early dose-finding trial, so the first goal is safety and finding a dose people can stay on. No placebo.

A broader KRAS-targeting trial for pancreatic cancer patients whose tumor has a KRAS mutation, even if it is not KRAS G12D.

🏥 Available in San Antonio, TX and Fairfax, VA | NCT07458347

B7-H7 immune engager for pancreatic cancer after standard treatments

This first-in-human study tests NPX372, a bispecific antibody designed to attach to B7-H7 on cancer cells and CD3 on T-cells. This type of drug is often called a T-cell engager because it brings immune cells close to cancer cells so they can attack.

Pancreatic cancer usually does not respond well to standard immunotherapy by itself. This trial uses a more direct immune approach: instead of simply “releasing the brakes” on the immune system, it tries to physically link T-cells to tumor cells. The study includes pancreatic cancer along with other hard-to-treat solid tumors, and pancreatic cancer is a clear fit because better immune-based options are badly needed after standard treatments stop working.

Expect IV treatment with close monitoring, especially early in the study, plus labs and scans. Doses may start low and increase carefully. No placebo.

A new immune-redirecting option for pancreatic cancer after standard treatments have stopped working.

🏥 Available in CA, MD, TN, TX, VA, and NY | NCT07563829

CLDN18.2-targeted “smart chemo” for CLDN18.2-positive pancreatic cancer

This trial tests ASP546C, an antibody-drug conjugate, or ADC. ADCs are sometimes called “smart chemo” because they use an antibody to find a marker on cancer cells and deliver a chemotherapy payload into those cells. ASP546C targets CLDN18.2 and carries a topoisomerase-1 chemotherapy payload.

CLDN18.2 is best known in stomach and gastroesophageal cancers, but it is also found in a subset of pancreatic cancers. It is not present in everyone, so study testing is required. For pancreatic cancer patients whose tumors are CLDN18.2-positive, this trial offers a marker-matched treatment after earlier therapy such as FOLFIRINOX, NALIRIFOX, gemcitabine/Abraxane, or Onivyde/5-FU.

Expect CLDN18.2 testing, IV infusions, regular labs, side-effect checks, and scans. This is an early study, so dose and safety are key parts of the trial. No placebo.

If your pancreatic tumor is CLDN18.2-positive, this offers a targeted drug-delivery option built around that marker.

🏥 Available in CA, MI, NY, TX, and UT | NCT07488676

Do you need help finding the right trial or getting connected?

Sagely Health offers a free, oncologist-reviewed Personalized Clinical Trial Shortlist for people with pancreatic cancer and other cancers. Share a few details—or upload records you already have—and receive a short, clear report focused on trials that may fit your diagnosis, treatments, biomarkers, and location.

Get Started

✍🏻 Do you have feedback? We’re listening at info@sagelyhealth.com or leave a comment!

Subscribe now

Pancreatic Cancer Trial Roundup

Each month, we do the hard work for you: finding newly recruiting studies, translating the medical language, and making it easier to see who each trial is for, what the treatment is trying to do, and why it may matter for people with pancreatic cancer.

This month, we see new options for locally advanced and metastatic pancreatic cancer, including KRAS-targeted treatment, biomarker-matched therapy, stroma-focused approaches, and new ways to deliver familiar drugs.

🔍 SEARCH TIP: Find Listings Matched to Your Situation

✅ 8 NEWLY RECRUITING TRIALS IN THIS BRIEFING

• 2 Trials for Newly Diagnosed PDAC (first-line treatment)

• 2 Trials for Locally Advanced PDAC (after prior treatment)

• 3 Trials for Metastatic or Locally Advanced PDAC (after prior treatment)

• 1 Trial for Metastatic PDAC (after prior treatment)

Need help narrowing down your clinical trial options?

If you want help finding trials that match your exact diagnosis, treatments, and biomarkers, Sagely Health offers a personalized trial report. Share a few details — or upload records you already have — and get a short, clear report focused on the trial options most worth discussing.

---

✅ Free · ✅ Confidential · ✅ Oncologist-reviewed

---

Get my free trial report

---

2 Trials for Newly Diagnosed PDAC

KRAS-targeted treatment added to first-line chemotherapy for KRAS G12D pancreatic cancer

This Phase 3 trial tests setidegrasib (ASP3082), a KRAS G12D-targeted drug, together with first-line chemotherapy. KRAS G12D is one of the most common KRAS changes in pancreatic cancer — roughly about one-third of metastatic PDAC in large sequencing cohorts — so this is not a rare niche strategy. Patients still need tumor testing to confirm KRAS G12D before this trial would apply. The usual first treatment for metastatic PDAC often includes mFOLFIRINOX or NALIRIFOX; this study asks whether directly going after KRAS G12D at the same time can help people live longer or keep the cancer under control longer than chemotherapy alone. Because this is a Phase 3 study, it is trying to answer a practical question that could matter for a large group of patients if the results are good.

Expect weekly IV study treatment plus chemotherapy on repeating 28-day cycles. This is a randomized, double-blind study, which means a computer assigns you to setidegrasib or placebo, and neither you nor your team chooses the group; everyone still receives active chemotherapy.

A high-interest first-line trial for people whose pancreatic cancer has a very common KRAS subtype and who want more than standard chemotherapy alone.

🏥 Available at many US locations | NCT07409272

FAK inhibitor added to mFOLFIRINOX for newly diagnosed metastatic pancreatic cancer

This Phase 1b/2a study adds narmafotinib (AMP945), a FAK inhibitor, to modified FOLFIRINOX in first-line metastatic PDAC. This trial is not limited to people with a specific tumor mutation or positive biomarker test. The target here is the cancer-supporting environment around pancreatic tumors, not a rare genetic subgroup. Pancreatic cancer often has a dense supportive tissue around it called stroma, which can make it harder for drugs and immune cells to do their job. This treatment is trying to change that environment so chemotherapy may work better. Standard first-line treatment for fit patients often uses modified FOLFIRINOX — 5-FU, leucovorin, irinotecan, and oxaliplatin — or gemcitabine plus nab-paclitaxel; this trial is testing whether adding a FAK inhibitor can make intensive chemotherapy work better or last longer. Because this is still an early study, a major goal is finding doses people can tolerate.

Expect a dose-finding part first, with close monitoring, then larger expansion groups once doses are chosen. The study drug is a pill, and mFOLFIRINOX is given by IV on a repeating schedule, with frequent early visits, labs, and scans.

A strong option for people starting treatment for metastatic PDAC who want a trial aimed at making standard chemotherapy work better, not just replacing it.

🏥 Available in New South Wales and Victoria, Australia, with U.S. sites opening | NCT07026279

2 Trials for Locally Advanced PDAC

Radiation-protective treatment designed to make SBRT easier on the gut in locally advanced pancreatic cancer

This Phase 1/2a study tests XER-001 together with SBRT for locally advanced unresectable pancreatic cancer after prior treatment. The goal is not to make radiation stronger against the tumor itself, but to help protect nearby normal tissue, especially in the upper GI tract, so focused radiation may be safer to give. For people with locally advanced disease who have already had chemotherapy, radiation can be useful for local control, but side effects can be a real concern because the pancreas sits close to sensitive organs. This early study is mainly trying to find a dose people can tolerate while also watching for signs that the overall approach is workable.

Expect dose-escalation treatment with the study drug delivered through a nasoduodenal route around the time of SBRT, along with close safety checks, blood tests, and follow-up scans. This is an open-label study, so there is no placebo group.

A practical trial for people with locally advanced disease who may benefit from SBRT but worry about how hard radiation can be on nearby digestive tissues.

🏥 Available in Santa Fe, NM, and Houston, TX | NCT07157033

Implanted device delivers gemcitabine directly into locally advanced pancreatic tumors

This first-in-human Phase 1b study tests ACT-IOP-003, an implanted device that pushes gemcitabine directly into pancreatic tumor-area tissue. This is not a new chemotherapy drug; it is a new way to deliver gemcitabine, a long-used pancreatic cancer chemotherapy drug that is often given by IV, either alone or with other drugs such as nab-paclitaxel. That matters in pancreatic cancer because the tumor and its surrounding tissue can be hard for drugs to penetrate well, while standard IV gemcitabine can also cause body-wide side effects. The study is for people with nonmetastatic, locally advanced pancreatic cancer after first-line treatment, and it asks whether local delivery can increase drug exposure in the tumor while lowering the amount that circulates through the rest of the body.

Expect a procedure to place the device, then once-weekly or twice-weekly treatments for about 8 weeks depending on the cohort, along with intensive safety checks, drug-level testing, and scans. This is an open-label early study focused mainly on safety and feasibility.

A thoughtful option for people with locally advanced disease who want a trial focused on getting more treatment into the tumor while possibly reducing whole-body side effects.

🏥 Available in Morgantown, WV | NCT07481383

3 Trials for Metastatic or Locally Advanced PDAC

EGFR-targeted treatment for the rare group with KRAS wild-type pancreatic cancer

This Phase 3 study adds panitumumab (Vectibix) to chemotherapy for pancreatic cancer that is KRAS wild-type. That matters because most pancreatic cancers do have a KRAS mutation. KRAS wild-type disease is a smaller group — roughly in the teens as a percentage of metastatic PDAC in large sequencing cohorts — but it is not vanishingly rare, so tumor sequencing can meaningfully identify patients who might fit this strategy. For this smaller group, there are still very few true targeted options. Standard second-line treatment often relies on more chemotherapy, such as liposomal irinotecan plus 5-FU/leucovorin after gemcitabine-based treatment, so this trial is asking whether blocking EGFR can improve results in a more biomarker-matched way. This may be especially relevant if testing shows your cancer lacks common MAPK-pathway changes.

Expect to be randomly assigned to chemotherapy plus panitumumab or chemotherapy alone. The chemotherapy backbone is chosen from a short list in the study, including options such as liposomal irinotecan plus 5-FU/leucovorin, irinotecan plus 5-FU/leucovorin, or gemcitabine plus nab-paclitaxel, depending on the patient’s prior treatment and study rules. You can expect regular IV visits, labs, and scans; there is no “no-treatment” group.

One of the clearest biomarker-driven options right now for the small group of people with KRAS wild-type pancreatic cancer.

🏥 Available at many U.S. sites across multiple states | NCT06998940

FAP-activated chemo designed to switch on mainly inside the tumor

This Phase 1 study tests AVA6103, a treatment designed to stay quieter in the body and become more active in the tumor area, where fibroblast activation protein (FAP) is often found. FAP is not a classic cancer-cell mutation like KRAS; it is often found in the tumor-supporting stroma of PDAC, and published IHC studies suggest FAP expression is common in pancreatic cancer tissue. This means the idea could be relevant to many PDAC patients, although this early trial still uses its own rules for which tumor types are considered likely to be FAP-positive. That is especially interesting in pancreatic cancer because PDAC often has a dense stroma rich in supportive cells around the tumor. Instead of targeting a mutation on the cancer cell itself, this approach uses the tumor environment as the trigger to release the chemo payload. This is an early study mainly trying to find safe doses and schedules, but it may be especially relevant for pancreatic cancer because of its biology.

Expect IV treatment every 2 or 3 weeks depending on the dose group, with frequent visits early on, blood tests, and scans. The first part of the study is mainly about safety, side effects, and finding a dose people can stay on.

A promising biology-matched early study for pancreatic cancer because it tries to use the tumor’s supportive tissue against the cancer.

🏥 Available in Irving, TX, and Fairfax, VA | NCT07454642

CLDN18.2-targeted ADC for the smaller group with CLDN18.2-positive pancreatic cancer

This Phase 1/2 study tests LCB02A, an antibody-drug conjugate aimed at CLDN18.2-positive tumors. CLDN18.2 is already a meaningful target in some GI cancers. In pancreatic cancer, published estimates vary depending on the test and cutoff: broad expression may be seen in around half of cases, but only about one-quarter may meet stricter, trial-like IHC thresholds. So this is a real subgroup, but screening is essential and many patients will not qualify. For the group whose tumor is CLDN18.2-positive, though, this is a clear biomarker-matched option. The treatment is designed to bind the target and deliver a cell-killing drug into the cancer cell. Early parts of the study focus on dose and safety; later parts look more closely at activity in selected tumor groups.

Expect IV treatment on a study schedule with regular clinic visits, lab work, and scans. Testing to confirm CLDN18.2 positivity is part of the key screening step, and prior CLDN18.2-directed treatment may still be allowed.

A strong match for the smaller subgroup with CLDN18.2-positive pancreatic cancer who need a treatment built around a confirmed tumor marker.

🏥 Available in Boston, MA; Charleston, SC; plus sites in Canada and South Korea | NCT07460375

1 Trial for Metastatic PDAC

EphA2-targeted “smart delivery” treatment after first-line therapy

This Phase 2 study tests BT5528 in metastatic pancreatic cancer after the cancer has already grown on or after first treatment. BT5528, also called nuzefatide pevedotin, is a Bicycle drug conjugate designed to home in on EphA2 and deliver a cell-killing payload called MMAE. EphA2 is not a mutation like KRAS; it is a surface protein target. Published PDAC tissue-array work suggests membranous EphA2 staining may be very common in pancreatic cancer. The key practical point is that this trial still requires EphA2 testing, because eligibility depends on the study’s assay and cutoff. For many people in this setting, treatment choices after first-line therapy are limited and often mean more standard chemotherapy. This trial offers a more targeted drug-delivery approach for patients whose tumors meet the study’s EphA2 expression requirement. Unlike some rare mutation-matched trials, EphA2 may be present in a relatively large share of PDAC samples, but the number of patients who qualify will depend on the trial’s specific staining threshold.

Expect IV treatment on a study schedule with regular safety visits, blood tests, and scans to see whether tumors shrink or stay stable. This is an open-label, single-arm study, so everyone enrolled receives BT5528.

A targeted post-first-line option for people whose tumor expresses EphA2 and who want something more selective than another standard chemo-only plan.

🏥 Available in Philadelphia, PA | NCT07450859

Do you need help finding the right trial or getting connected?

Sagely Health offers a premium, physician-led consultation service that pairs a thorough review of your records with direct introductions to world-class specialists and trial investigators. Our team translates the latest science into clear options, compares every promising treatment (standard or experimental), and makes warm hand-offs so you’re not left cold-calling clinics.

✍🏻 Do you have feedback? We’re listening at info@sagelyhealth.com or leave a comment!

Subscribe now